68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer

2018 ◽  
Vol 37 (5) ◽  
pp. 813-821 ◽  
Author(s):  
Elif Neslihan Akdemir ◽  
Murat Tuncel ◽  
Fadıl Akyol ◽  
Cenk Yucel Bilen ◽  
Dilek Ertoy Baydar ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ct Imaging ◽  
Recurrent Prostate Cancer ◽  
Psma Ligand ◽  
Pet Ct

scholarly journals The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

2014 ◽  
Vol 42 (2) ◽  
pp. 197-209 ◽  
Author(s):  
Ali Afshar-Oromieh ◽  
Eleni Avtzi ◽  
Frederik L. Giesel ◽  
Tim Holland-Letz ◽  
Heinz G. Linhart ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Diagnostic Value ◽  
Ct Imaging ◽  
Recurrent Prostate Cancer ◽  
Psma Ligand ◽  
Pet Ct

Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer

2019 ◽  
Vol 103 (1) ◽  
pp. 95-104 ◽  
Author(s):  
Alexander Soldatov ◽  
Christoph A.J. von Klot ◽  
Daniel Walacides ◽  
Thorsten Derlin ◽  
Frank M. Bengel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Recurrent Prostate Cancer ◽  
Ct Guided ◽  
Psma Ligand ◽  
Pet Ct

A review discussing fluciclovine (18F) PET/CT imaging in the detection of recurrent prostate cancer

2018 ◽  
Vol 14 (11) ◽  
pp. 1101-1115 ◽  
Author(s):  
Lucia Zanoni ◽  
Irene Bossert ◽  
Antonella Matti ◽  
Riccardo Schiavina ◽  
Cristian Pultrone ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Ct Imaging ◽  
Recurrent Prostate Cancer ◽  
Pet Ct

Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis

2019 ◽  
Vol 46 (11) ◽  
pp. 2289-2297 ◽  
Author(s):  
Ali Afshar-Oromieh ◽  
Bernd Vollnberg ◽  
Ian Alberts ◽  
Alexandrine Bähler ◽  
Christos Sachpekidis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Multiparametric Mri ◽  
Recurrent Prostate Cancer ◽  
Psma Ligand ◽  
Pet Ct

scholarly journals 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy

2019 ◽  
Vol 61 (6) ◽  
pp. 881-889 ◽  
Author(s):  
Esther Mena ◽  
Maria Liza Lindenberg ◽  
Ismail Baris Turkbey ◽  
Joanna H. Shih ◽  
Stephanie A. Harmon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Local Therapy ◽  
Ct Imaging ◽  
Recurrent Prostate Cancer ◽  
Pet Ct

scholarly journals Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

2013 ◽  
Vol 41 (1) ◽  
pp. 11-20 ◽  
Author(s):  
Ali Afshar-Oromieh ◽  
Christian M. Zechmann ◽  
Anna Malcher ◽  
Matthias Eder ◽  
Michael Eisenhut ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pet Imaging ◽  
Recurrent Prostate Cancer ◽  
Psma Ligand ◽  
Pet Ct

scholarly journals Detection Rate of 68Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy

Biomedicines ◽  
2020 ◽  
Vol 8 (11) ◽  
pp. 511
Author(s):  
Joachim Brumberg ◽  
Melanie Beckl ◽  
Alexander Dierks ◽  
Andreas Schirbel ◽  
Markus Krebs ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Detection Rate ◽  
Androgen Deprivation ◽  
Disease Stage ◽  
Whole Body ◽  
Recurrent Prostate Cancer ◽  
Detection Rates ◽  
Psma Ligand ◽  
Pet Ct

Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the detection rate of 68Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy and 68Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score matching was used to create two balanced groups of 62 subjects who either did or did not receive ADT within six months before imaging. All 68Ga-PSMA ligand PET/CT were evaluated visually and with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in the group with ADT (88.7% vs. 72.6%, p = 0.02) and improved with increasing PSA-levels in both groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (p < 0.01) and PSMA-derived tumor volume (p < 0.01) were significantly higher than in those without ADT. More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to high detection rates in patients with PSA-levels < 2 ng/mL, the withdrawal of ADT before PSMA ligand PET/CT cannot be recommended.

Sign in / Sign up

Export Citation Format

Share Document